Results 181 to 190 of about 112,978 (213)

Population pharmacokinetics of imipenem in different populations for individualized dosing: a systematic review. [PDF]

Front Pharmacol
Zhang P, Zhao Y, Zhu J, Yang Y, Liang G, Wang X, Yu Z.   +6 more
europepmc   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Population pharmacokinetics of efpeglenatide in individuals with obesity and with type 2 diabetes. [PDF]

Front Pharmacol
Choi S, Seo J, Park S, Kim NY, Kim H, Lim HS.   +5 more
europepmc   +1 more source

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity

Arthritis &Rheumatology, Accepted Article.
Joseph F. Merola, Cynthia E. Kartman, Peter Fischer, Luna Sun, Anabela Cardoso, Mark C. Genovese, Alexis Ogdie   +6 more
wiley   +1 more source

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić, Christina Antza, Anastasios Poutachidis, Smaro Palaska, Elvira Meni Maria Gkrinia, Andrea Katrin Faour, Yusuf Ziya Sener, Seher Sener, Rehena Sultana   +8 more
wiley   +1 more source

Population Pharmacokinetics of Asundexian in People at Risk for Thromboembolic/Cardiovascular Events. [PDF]

CPT Pharmacometrics Syst Pharmacol
Yassen A, Kanefendt F, Zisowsky J, Broeker A, Mundl H, Vis P, Garmann D, Berkhout J.   +7 more
europepmc   +1 more source

Population Pharmacokinetics and Exposure-Response Analyses for Telisotuzumab Vedotin in Patients With c-Met Protein Overexpressing Tumors. [PDF]

CPT Pharmacometrics Syst Pharmacol
Babel H, Brunsdon P, Engelhardt B, Schmitt V, Ratajczak C, Mensing S, Menon RM, Parikh A.   +7 more
europepmc   +1 more source

Population pharmacokinetics of tenofovir alafenamide delivered via an annual subdermal implant in South African women. [PDF]

Sci Rep
Beliveau M, Chang C, Lewis L, Letsoalo MP, Karim QA, Karim SSA, Marzinke MA, Moss JA, Gengiah TN, Baum MM.   +9 more
europepmc   +1 more source

Population Pharmacokinetics and Model-Informed Dose Optimization of Teicoplanin in Adults with Hematological Malignancies. [PDF]

Pharmaceutics
García-Hervalejo M, Sánchez-Hernández JG, Conde-González I, Avendaño Pita A, Otero MJ.   +4 more
europepmc   +1 more source

Population pharmacokinetics/pharmacodynamics and safety of YPEG-rhGH in elderly subjects. [PDF]

Front Pharmacol
He Y, Hu J, Zeng X, Yang Q, You Q, Huang J, Zhang Y, Si L, Zhai X.   +8 more
europepmc   +1 more source